These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 20409934)

  • 21. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome.
    Kakuma T; Gotoh K; Masaki T; Itateyama E; Abe N; Yoshimatsu H
    Obes Res Clin Pract; 2010; 4(2):e83-e162. PubMed ID: 24345653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-A(y) Diabetic Mice.
    Takasu T; Kakuta H; Sasamata M; Yamagishi S
    Int J Biomed Sci; 2006 Dec; 2(4):333-6. PubMed ID: 23675001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pleiotropic effects of ARB in metabolic syndrome.
    Yamada S
    Curr Vasc Pharmacol; 2011 Mar; 9(2):158-61. PubMed ID: 21143168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between antihypertensive drugs and metabolic syndrome.
    Wofford MR; King DS
    Metab Syndr Relat Disord; 2004; 2(4):308-14. PubMed ID: 18370699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of angiotensin II receptor antagonists in the treatment of metabolic syndrome].
    Botella Carretero JI; Fresneda Moreno J; Manzano Espinosa L
    Rev Clin Esp; 2006 Jun; 206(6):284-8. PubMed ID: 16762293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of angiotensin receptor blockers (ARBs) in the metabolic syndrome].
    Sasamura H; Itoh H
    Nihon Rinsho; 2007 Feb; 65(2):381-8. PubMed ID: 17302287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 7th Brazilian Guideline of Arterial Hypertension: Chapter 10 - Hypertension in Children and Adolescents.
    Malachias MVB; Koch V; Colombo C; Silva S; Guimarães IC; Nogueira PK
    Arq Bras Cardiol; 2016 Sep; 107(3 Suppl 3):53-63. PubMed ID: 27819389
    [No Abstract]   [Full Text] [Related]  

  • 31. The metabolic cost of lowering blood pressure with hydrochlorothiazide.
    Price AL; Lingvay I; Szczepaniak EW; Wiebel J; Victor RG; Szczepaniak LS
    Diabetol Metab Syndr; 2013 Jul; 5(1):35. PubMed ID: 23837919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational use of antihypertensive medications in children.
    Ferguson MA; Flynn JT
    Pediatr Nephrol; 2014 Jun; 29(6):979-88. PubMed ID: 23715784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does it matter how blood pressure is lowered in patients with metabolic risk factors?
    Sharma AM
    J Am Soc Hypertens; 2008; 2(4 Suppl):S23-9. PubMed ID: 20409934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.